# Clinical biomarkers predicting response to IVIG therapy

## Predictive biomarkers for IVIG response are disease-specific: 
Pre-treatment inflammatory markers (C-reactive protein, liver enzymes, bilirubin) predict resistance in Kawasaki disease, while post-treatment cellular immune markers (NK cells, regulatory T cells) predict response in chronic neurological autoimmune disorders.

# Abstract
Clinical biomarkers predicting IVIG response differ substantially by disease condition and reflect distinct pathophysiological mechanisms. In Kawasaki disease, pre-treatment inflammatory markers consistently predicted resistance: C-reactive protein (cut-offs 7-10 mg/dL), liver transaminases (AST ≥200 IU/L, ALT ≥80 IU/L), and total bilirubin (≥0.9 mg) demonstrated significant associations with non-response in multivariate analyses. Composite prediction scores combining multiple markers achieved 76-78% sensitivity and specificity. Post-treatment inflammatory markers measured 24 hours after infusion showed superior performance, with total leucocyte count >13.1×10⁹/L achieving 91% sensitivity and 89% specificity. In contrast, autoimmune neurological disorders demonstrated no predictive value for inflammatory markers. Instead, post-treatment cellular immune biomarkers proved informative: NK cell markers (CD56bright, KLRB1, KLRK1) measured 24 hours after IVIG initiation significantly discriminated CIDP responders from non-responders (p=0.007-0.027), while regulatory T cell frequency correlated with clinical recovery in Guillain-Barré syndrome. In dermatomyositis, higher baseline cutaneous disease activity predicted better response, whereas higher pulmonary activity predicted lower response. These divergent biomarker profiles reflect condition-specific IVIG mechanisms: acute inflammation suppression in Kawasaki disease versus immune cell modulation in chronic neurological disorders. Clinical consequences of non-response varied substantially, with Kawasaki disease non-responders experiencing coronary artery abnormalities at rates of 38-71% versus 1-5% in responders.

## Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question. More on methods

Records from Elicit search

- n = 200  
- Papers screened using: IVIG Therapy, Biomarker-Response Relationship, Biomarker Measurement, Response Criteria, Study Type, Human Subjects, Baseline Biomarker Assessment, Sample Size  
- n = 200  
- Papers screened out  
- n = 190  
- Papers included for extraction  
- n = 10

## Data extraction
- **Medical Condition**: Extract the specific medical condition or indication for which IVIG therapy was administered (e.g., Guillain-Barré syndrome, Kawasaki disease).
- **Biomarker Details**: Extract all clinical biomarkers tested for predicting IVIG response.
- **IVIG Response Definition**: Extract how IVIG treatment response was defined and measured.
- **Biomarker Performance**: Extract the predictive performance of each biomarker for IVIG response.
- **IVIG Protocol**: Extract details of the IVIG treatment protocol used.
- **Study Population**: Extract characteristics of the study population relevant to biomarker performance.
- **Clinical Outcomes**: Extract the actual clinical outcomes observed in responders vs non-responders to IVIG.

## Results
### Characteristics of Included Studies
Ten studies investigating clinical biomarkers for predicting IVIG response were identified, spanning multiple autoimmune and inflammatory conditions. Five studies (50%) had full text available for detailed review.

| Study | Full text retrieved? | Medical Condition | Sample Size | IVIG Dose | Response Definition |
|---|---|---|---|---|---|
| Y. Levy et al., 1999 | No | Systemic lupus erythematosus | 20 | 2 g/kg monthly over 5 days | Binary; clinical improvement with decreased SLAM score |
| A. Irgens et al., 2012 | No | Myasthenia gravis with worsening weakness | 51 | 2 g/kg divided over 2 days | Continuous; change in QMG Score at day 14 |
| C. Charles-Schoeman et al., 2025 | No | Dermatomyositis | 95 | 2.0 g/kg every 4 weeks | Continuous; total improvement score (TIS) |
| J. Hwang et al., 2010 | No | Kawasaki disease | 229 (206 responders, 23 non-responders) | Not specified | Binary; responder vs non-responder |
| M. Maddur et al., 2017 | Yes | Guillain-Barré syndrome | 10 | 0.4 g/kg for 3-5 consecutive days | Continuous; MRC and modified Rankin scores |
| T. Sano et al., 2006 | No | Acute Kawasaki disease | 112 | 2 g/kg within 2 days of onset | Binary; responsive vs non-responsive |
| Anne K. Mausberg et al., 2020 | Yes | Chronic inflammatory demyelinating polyneuropathy | 29 | Not specified, treatment up to 6 months | Binary; INCAT score decline ≥1 point over 6 months |
| K. Egami et al., 2006 | No | Kawasaki disease | 320 (279 responders, 41 resistant) | 2 g/kg within 9 days of illness | Binary; resistance vs responder groups |
| J. Abe et al., 2008 | No | Kawasaki disease | Not specified | High-dose (not specified) | Binary; responsive vs nonresponsive |
| Mariko Fukunishi et al., 2000 | No | Kawasaki disease | 82 (69 responsive, 13 non-responsive) | High-dose (not specified) | Binary; defervescence within 5 days |

The studies represented diverse autoimmune conditions, with Kawasaki disease being the most extensively studied (5/10 studies). Sample sizes ranged from 10 to 320 patients. Most studies used standard high-dose IVIG protocols of 2 g/kg, though administration schedules varied. Response definitions were predominantly binary (responder vs non-responder), though some studies used continuous outcome measures.

## Predictive Biomarkers by Disease Category
### Kawasaki Disease
Five studies examined biomarkers predicting IVIG resistance in Kawasaki disease, demonstrating substantial heterogeneity in both biomarkers identified and their measurement timing. Pre-treatment inflammatory markers emerged as consistent predictors across multiple studies.

| Study | Pre-treatment Biomarkers | Cut-off Values | Performance Metrics | Post-treatment Biomarkers |
|---|---|---|---|---|
| T. Sano et al., 2006 | CRP, total bilirubin, AST, ALT, LDH, neutrophil count | CRP ≥7.0 mg, TB ≥0.9 mg, AST ≥200 IU/L | Multivariate p-values: CRP (p=0.009), TB (p<0.001), AST (p=0.002) | Not assessed |
| K. Egami et al., 2006 | Age, illness days, platelet count, ALT, CRP | Age <6 months, <4 illness days, platelet ≤30×10¹⁰/L, CRP ≥8 mg/dL, ALT ≥80 IU/L | Prediction score sensitivity 78%, specificity 76% | Not assessed |
| Mariko Fukunishi et al., 2000 | CRP, total bilirubin, LDH, gamma-glutamyltranspeptidase, hemoglobin | CRP >10 mg/dL, LDH >590 IU/L, hemoglobin <10 g/dL | Multivariate p-values: CRP (p=.006), LDH (p=.035), TB (p=.046) | Not assessed |
| J. Hwang et al., 2010 | Neutrophil differential, CRP | Pre-treatment: neutrophil >51% | Not specified | Total leucocyte >13.1×10⁹/L (sens 91%, spec 89%), neutrophil >51% (sens 91%, spec 76%) |
| J. Abe et al., 2008 | Polycythemia rubra vera 1, G-CSF measured by mRNA and protein levels | Not specified | Higher in nonresponders | Not assessed |

C-reactive protein emerged as the most consistently identified pre-treatment biomarker, appearing in four of five Kawasaki studies. However, optimal CRP cut-off values varied considerably across studies: ≥7.0 mg in Sano et al., ≥8 mg/dL in Egami et al., and >10 mg/dL in Fukunishi et al. Liver enzymes (AST, ALT) and total bilirubin also demonstrated predictive value in multiple studies.

Notably, J. Hwang et al. uniquely examined post-treatment biomarkers measured 24 hours after IVIG infusion. Total leucocyte count >13.1×10⁹/L demonstrated the highest combined sensitivity (91%) and specificity (89%), suggesting that early post-infusion inflammatory markers may complement pre-treatment predictors.

Non-responders to IVIG consistently demonstrated worse clinical outcomes. Coronary artery abnormalities occurred at substantially higher rates in non-responders: 71% versus 5% in Sano et al., 38.5% versus 1.4% in Fukunishi et al.. Response rates to initial IVIG treatment ranged from 84-87.5% across studies.

### Autoimmune Neurological Disorders
Three studies examined biomarkers in distinct neurological conditions, revealing markedly different predictive approaches.

In Guillain-Barré syndrome, Maddur et al. investigated regulatory T cell (Treg) frequency as a post-treatment biomarker. Treg cells were measured by flow cytometry for surface CD4 and intracellular Foxp3 at baseline and weeks 1, 2, and 4-5 post-IVIG. Clinical recovery correlated with Treg cell response, suggesting Treg frequency represents a potential immunological biomarker. Critically, plasma IL-33 levels showed no correlation with clinical response scores (MRC and MRS) at any timepoint, contradicting murine model predictions and highlighting species-specific differences in IVIG mechanisms.

For chronic inflammatory demyelinating polyneuropathy (CIDP), Mausberg et al. identified natural killer (NK) cell markers measured 24 hours post-IVIG initiation as predictive. CD56bright NK cells and gene transcripts KLRB1 and KLRK1 demonstrated significant association with response, with p-values of 0.007, 0.027, and 0.010 respectively. The observed effects on NK cells occurred almost exclusively in IVIG-responsive patients, with CD56dim cytotoxic NK cells decreasing while CD56bright regulatory NK cells remained stable or increased. Approximately 70% of CIDP patients responded to IVIG, with nonresponders requiring 2-6 months for identification based on lack of INCAT score improvement.

In myasthenia gravis, Irgens et al. used the QMG Score for Disease Severity as both outcome measure and potential severity stratification tool. Patients with baseline QMG >10.5 (more severe disease) demonstrated the greatest improvement, suggesting baseline severity may predict magnitude of response. The study provided level 1 evidence for IVIG effectiveness, with clinically meaningful improvement (≥3.5 U change in QMG score) observed at day 14 and persisting at day 28.

### Other Autoimmune Conditions
In systemic lupus erythematosus, Levy et al. examined autoantibodies and complement levels as potential predictors. Biomarkers assessed included ANA, dsDNA, SS-A/SS-B, ENA, C3, and C4, measured before and after each treatment course. Treatment responders showed a tendency toward abnormal complement and antibody levels pre-treatment with subsequent normalization, reaching statistical significance only for C4 and SS-A/SS-B levels. Overall response rate was 85% (17/20 patients), with SLAM scores decreasing from 19.3±4.7 to 4±2.9 (p<0.0001).

For dermatomyositis, Charles-Schoeman et al. in the ProDERM study examined clinical disease activity scores and myositis-associated autoantibodies. Multivariate analysis identified higher MDAAT cutaneous scores as predicting better TIS improvement, while higher MDAAT pulmonary scores associated with lower (though still considerable) improvement likelihood.

## Synthesis
The heterogeneity in predictive biomarkers across conditions reflects fundamental differences in disease pathophysiology, IVIG mechanisms of action, and optimal measurement timing rather than inconsistent or contradictory findings.

**Disease-Specific Biomarker Patterns**
For Kawasaki disease, acute inflammatory markers (CRP, liver enzymes, bilirubin) consistently predicted resistance when measured pre-treatment. This pattern aligns with the disease’s pathophysiology as an acute systemic vasculitis where hyperinflammation drives IVIG resistance.

**Timing of Biomarker Measurement**
The optimal measurement timing varied systematically by condition and biomarker type. Pre-treatment inflammatory markers predicted response in Kawasaki disease, while post-treatment cellular immune markers predicted response in CIDP and Guillain-Barré syndrome.

**Composite Prediction Scores**
Two Kawasaki studies developed composite prediction scores combining multiple biomarkers.

**Clinical Outcome Implications**
The clinical consequences of IVIG non-response differed markedly by condition. In Kawasaki disease, non-responders faced dramatically elevated risks of coronary artery abnormalities, whereas in CIDP, non-response required an extensive timeframe to identify.

**Generalizability Across Populations**
Disease severity emerged as a crucial modifier of IVIG response across conditions.

**Methodological Considerations**
The predominance of studies with abstract-only data limits assessment of potential confounders, statistical methodologies, and missing data handling.